empty
 
 
ro
Search
Support
Instant account opening
Trading Platform
Deposit/Withdraw
Search
Pentru Începători Pentru Traderi Pentru Parteneri Luați o pauză Despre InstaSpot
ro
#BGNE Reveniți la lista instrumentelor #BMY

Convertor valutar

Biogen Inc.
156.16 USD
26 Nov 2024 17:40
Modificarea pretului (% chg)
$-0.3
(-0.19%)
Inchidere
Inchidere

Pretul de inchidere, ziua precedenta.
$158.36
Deschiderea
Deschiderea

Pretul de deschidere.
$159.88
Petul maxim
Petul maxim

Pretul maxim al ultimei zile de tranzactionare.
$159.73
Pretul minim
Pretul minim

Pretul minim al ultimei zile de tranzactionare.
$156.38
52-sapt. max.
52-sapt. max.

Pretul maxim din ultimele 52 spatamani.
$159.77
52-sapt. min.
52-sapt. min.

Pretul minim din ultimele 52 saptamani.
$156.38
Descărcați arhiva
Cumpărați
156.16
Vindeți
156.16
Deschideți graficul în ecran complet
Cumpărați
156.16
Vindeți
156.16
Descărcați arhiva
Deschideți graficul în ecran complet

Biogen Inc. About company

Biogen Inc. is an American biopharmaceutical company founded in 1978. Initially, the company was headquartered in Switzerland, with all studies being conducted in European countries. Later, most of the company’s research centers were moved to the United States.

Biogen Inc. is engaged in the production of drugs based on DNA studies. At present, the company produces drugs used to treat multiple sclerosis, SMA, Alzheimer's disease, and other disorders.

Biogen’s market cap is $38.33 billion. Last year, its annual revenue stood at $10.981 billion, with net income at $1.556 billion.

Biogen’s shares and factors affecting their value

Its stock has been listed on the NASDAQ exchange under the ticker BIIB since 1983. The initial share price was $23.

Today, the company's shares are worth $257-$267. Over the past year, their value has ranged from $187 to $291.

When trading Biogen’s stock, traders are recommended to keep track of:

  • The products manufactured by the drugmaker are in demand. Moreover, their relevance is bound to increase in the future due to the world's aging population as well as progressive diseases among the elderly;
  • If the company passes clinical trials and receives a patent for a drug, it provides itself with an opportunity to make profits for at least 12 years, while other companies are prohibited from releasing analogues;
  • If Aducanumab receives approval as a treatment for Alzheimer's disease, the company’s capitalization will increase several times;
  • The company has good prospects in the market as it is greatly underestimated in comparison to competitors.

Nu puteti sa vorbiti acum?
Puneti intrebare in chat.